Use of EGFR transactivation inhibitors in human cancer

Details for Australian Patent Application No. 2003219029 (hide)

Owner Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V

Inventors Fischer, Oliver; Ullrich, Axel; Gschwind, Andreas; Schafer, Beatrix; Leserer, Michael

Agent Davies Collison Cave

Pub. Number AU-B-2003219029

PCT Number PCT/EP03/02361

PCT Pub. Number WO2003/075947

Priority 02005452.4 08.03.02 EP

Filing date 7 March 2003

Wipo publication date 22 September 2003

Acceptance publication date 11 September 2008

International Classifications

A61K 38/16 (2006.01) Medicinal preparations containing peptides - Peptides having more than 20 amino acids

A61K 38/18 (2006.01) Medicinal preparations containing peptides - Growth factors

A61K 38/48 (2006.01) Medicinal preparations containing peptides

A61K 38/55 (2006.01) Medicinal preparations containing peptides - Protease inhibitors

Event Publications

31 July 2003 Complete Application Filed

  Priority application(s): 02005452.4 08.03.02 EP

30 October 2003 Application Open to Public Inspection

  Published as AU-B-2003219029

11 September 2008 Application Accepted

  Published as AU-B-2003219029

22 January 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003219030-DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN G PROTEIN-COUPLED ORPHAN RECEPTOR 21 (GPR21)

2003219028-NON-PRIMATE FXRb AS A LANOSTEROL SENSING NUCLEAR HORMONE RECEPTOR AND RELATED USES